NEW YORK, NY / ACCESSWIRE / January 25, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SI Shareholders Click Here: https://www.zlk.com/pslra-1/silvergate-capital-loss-submission-form?prid=35934&wire=1
TWST Shareholders Click Here: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35934&wire=1
FATE Shareholders Click Here: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=35934&wire=1

* ADDITIONAL INFORMATION BELOW *

Silvergate Capital Corporation (NYSE:SI)

SI Lawsuit on behalf of: investors who purchased November 11, 2020 - January 5, 2023
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/silvergate-capital-loss-submission-form?prid=35934&wire=1

According to the filed complaint, during the class period, Silvergate Capital Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's platform lacked sufficient controls and procedures to detect instances of money laundering; (2) Silvergate's customers had engaged in money laundering in amounts exceeding $425 million; (3) as a result of the foregoing, the Company was reasonably likely to receive regulatory scrutiny and face damages, including penalties and reputational harm; and (4) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Twist Bioscience Corporation (NASDAQ:TWST)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.
Lead Plaintiff Deadline : February 10, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35934&wire=1

According to the filed complaint, 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist's synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company's true financial condition and prospects.

Fate Therapeutics, Inc. (NASDAQ:FATE)

FATE Lawsuit on behalf of: investors who purchased April 2, 2020 - January 5, 2023
Lead Plaintiff Deadline : March 22, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=35934&wire=1

According to the filed complaint, during the class period, Fate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the global collaboration and option agreement for cell-based cancer immunotherapies that the Company entered into with Janssen Biotech, Inc. (the 'Janssen Collaboration Agreement') was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement's on Fate's long-term clinical and commercial profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP